SHR-1210
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma Non-Resectable
Conditions
Hepatocellular Carcinoma Non-Resectable
Trial Timeline
Nov 15, 2016 → Mar 3, 2020
NCT ID
NCT02989922About SHR-1210
SHR-1210 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Hepatocellular Carcinoma Non-Resectable. The current trial status is completed. This product is registered under clinical trial identifier NCT02989922. Target conditions include Hepatocellular Carcinoma Non-Resectable.
What happened to similar drugs?
5 of 20 similar drugs in Hepatocellular Carcinoma Non-Resectable were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03558191 | Phase 2 | Completed |
| NCT03557411 | Phase 2 | UNKNOWN |
| NCT03363555 | Phase 2 | UNKNOWN |
| NCT03222440 | Pre-clinical | Completed |
| NCT03155425 | Phase 2 | Completed |
| NCT03085069 | Phase 2 | UNKNOWN |
| NCT02989922 | Phase 2 | Completed |
| NCT02738489 | Phase 1 | Completed |
| NCT02721589 | Phase 1 | Completed |
Competing Products
20 competing products in Hepatocellular Carcinoma Non-Resectable